Take part in a paid clinical trial

This study is exploring a potential new therapy aimed at helping slow disease progression and improve outcomes for people living with idiopathic pulmonary fibrosis. This research is made possible with Healthy Volunteers.

Idiopathic pulmonary fibrosis, or IPF, is a long-term lung condition where the tissue in the lungs slowly becomes scarred and stiff.

Normally, your lungs are soft and stretchy, which makes it easy to breathe and for oxygen to pass into your blood. With IPF, scar tissue builds up in the lungs over time, making them thicker and harder. As this scarring increases, it becomes more difficult to breathe and harder for the body to get the oxygen it needs.

The purpose of this study is to evaluate how the experimental drug is processed in the body and to assess potential interactions between the study drug and medications currently approved for idiopathic pulmonary fibrosis (IPF).

Epstein–Barr virus (EBV) is a very common virus that infects more than 9 out of 10 adults worldwide. It is best known for causing infectious mononucleosis, sometimes called “glandular fever or mono ”, particularly when infection occurs during the teenage years or early adulthood.

EBV has also been linked to certain cancers, autoimmune conditions, and multiple sclerosis.

Once a person is infected, EBV remains in the body for life. The virus usually stays inactive (dormant), but it can reactivate from time to time, often without causing symptoms.

The study vaccine uses mRNA technology, which has been widely used and studied in COVID‑19 vaccines. mRNA vaccines provide instructions to the body that help the immune system recognise and fight a virus. The mRNA does not contain live virus and does not remain in the body.

We’re currently looking for adults aged 18 to 65 who are experiencing androgenetic alopecia (AGA), also known as pattern hair loss, to take part in The Headline Trial.

Hair loss is common and can affect both men and women. This clinical study is investigating new approaches that may help shape future treatment options.

You don’t need a formal diagnosis to get started. If you think you may have AGA, you can begin with a quick pre-screen. This helps us assess whether you may meet the initial study requirements. Completing the pre-screen doesn’t guarantee enrolment, but it’s an important first step in seeing whether the study may be suitable for you.

By getting involved, you’ll be contributing to research that aims to improve future options for people affected by hair loss.

This study is exploring a potential new treatment designed to reduce inflammation and improve skin health in people living with chronic conditions like psoriasis and hidradenitis suppurativa. The goal is to better understand how this therapy works in the body—how it’s processed, tolerated, and whether it can offer meaningful relief. By participating, you’ll help researchers shape future treatments that are more effective, inclusive, and designed for real life.